Leucid Bio Initiates AERIAL Trial for NKG2D CAR-T Therapy
Leucid Bio, a groundbreaking biotech firm, has made headlines with its latest announcement regarding the Phase 1 AERIAL trial. This trial focuses on evaluating the safety and clinical efficacy of their CAR-T therapy, LEU011, targeting solid tumors. The commencement of this trial marks a pivotal moment for the company, as it aims to push the boundaries of cancer treatment.
Significant Funding Boost
Accelerating the initiation of the AERIAL trial was the successful first close of Series A1 financing, which brought in an impressive £7.2 million. This funding round, co-led by strategic investors, brings the total Series A funding to £18.7 million, ensuring that Leucid has the necessary resources to move forward with the trial.
Details of the AERIAL Trial
The AERIAL trial is designed as a multi-centre, dose-escalation study. It involves administering a single intravenous dose of LEU011 following preconditioning chemotherapy to patients who have refractory solid tumors. This design aims to gather initial proof-of-concept data by the second half of the year 2025, which will significantly contribute to understanding the therapy's performance in clinical settings.
NKG2D CAR-T Therapy Overview
LEU011 is a unique autologous lateral CAR-T cell therapy that specifically targets NKG2D ligands. These ligands are known to be overexpressed on over 80% of human tumor cells, including their surrounding microenvironment. The innovation behind LEU011 includes the engineering of the chemokine receptor, CXCR2, which is intended to improve the therapy's efficacy by enhancing cell trafficking and tumor infiltration. This addition is crucial as it addresses some of the well-known limitations faced by existing CAR-T therapies in solid tumor applications.
Manufacturing Excellence
Leucid Bio is proud to announce that LEU011 is the first CAR-T candidate manufactured at the Zayed Centre for Research at Great Ormond Street Hospital (GOSH). This state-of-the-art facility is known for its compliance with Good Manufacturing Practice (GMP) standards, ensuring high-quality production processes. This partnership, forged through an agreement announced earlier, emphasizes Leucid’s commitment to pushing the frontiers of cell therapy manufacturing.
Leadership Perspectives
Filippo Petti, the CEO of Leucid Bio, expressed enthusiasm about the trial's initiation, stating that it marks a significant milestone for the company. He highlighted the impressive preclinical anti-tumor activities that LEU011 demonstrated and its potential to address the challenges seen in refractory solid tumors. Working alongside the experts at GOSH has enabled Leucid to accelerate the development of this promising therapy.
Stephen Mathew, head of innovation at GOSH, also shared his delight about the collaboration. He remarked that manufacturing LEU011 at their facility showcases their shared goal of driving innovation in cell and gene therapies. The AERIAL trial's initiation represents a hopeful milestone for developing potentially curative treatments for patients facing complex healthcare challenges.
About Leucid Bio
Leucid Bio is dedicated to pioneering cell therapies for solid tumors through its proprietary lateral CAR platform. Their lead asset, LEU011, is engineered to target NKG2D ligands present on a majority of human tumors, thus representing a significant advancement in CAR-T therapies. With CXCR2 co-expression to enhance trafficking, LEU011 positions itself as a strong candidate in oncology.
About Great Ormond Street Hospital
Great Ormond Street Hospital for Children NHS Foundation Trust is a renowned institution specializing in children’s healthcare. It brings together a multitude of specialists and provides innovative treatments to pediatric populations across the globe. The facility is home to the Zayed Centre for Research into Rare Diseases, emphasizing its role in translating research breakthroughs into effective clinical treatments.
Frequently Asked Questions
What is the AERIAL trial by Leucid Bio?
The AERIAL trial is a Phase 1 study focused on evaluating the safety and efficacy of the LEU011 CAR-T therapy for patients with refractory solid tumors.
How much funding has Leucid Bio raised for the AERIAL trial?
Leucid Bio has raised a total of £18.7 million through Series A funding, with the initial close of £7.2 million accelerating the AERIAL trial's initiation.
What is LEU011 and how does it work?
LEU011 is an autologous lateral CAR-T cell therapy targeting NKG2D ligands, designed to enhance cell trafficking and tumor infiltration, aiming to improve treatment efficacy for solid tumors.
Where is LEU011 manufactured?
LEU011 is manufactured at the Zayed Centre for Research at Great Ormond Street Hospital, ensuring high-quality production via GMP-compliant facilities.
What is the potential impact of the AERIAL trial?
The trial aims to generate initial data on LEU011's effectiveness, potentially paving the way for new treatment options for patients with challenging solid tumors.
